Syngene International Ltd. is a leading Integrated Innovation Partner and CRDMO, for the global pharmaceutical, biopharma, biotechnology, and life sciences investment sectors. By combining discovery science, development expertise, and scalable manufacturing under one roof, we eliminate handoff delays, anticipate technical challenges, and align strategies to shorten timelines and reduce risk. As an innovation partner, we connect every stage from concept to IND. With expertise across biologics, ADCs, and targeted protein degradation, we deliver speed, scientific depth, and strategic alignment. Our proprietary SynTACs™ platform advances induced proximity-based therapeutics such as PROTACs, while our AI-driven ecosystem—Syn.AI™, SARchitect™, and SynTIPS™—optimizes design, accelerates analysis, and delivers actionable insights. Powered by our SynVent™ integrated discovery engine, we transform early-stage ideas into viable clinical candidates. Through versatile partnering structures and tailored business models, Syngene supports more than 400 global customers—including leading biotech innovators and multinational companies such as BMS, GSK, Zoetis, and Merck KGaA—to accelerate drug pipelines with capital efficiency, scientific rigor, and world-class manufacturing excellence. | . | Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical sectors. Syngene’s more than 5000 scientists offer both skills and the capacity to deliver great science, robust data security, and world-class manufacturing at speed to improve time-to-market and lower the cost of innovation. With a combination of dedicated research facilities for Baxter, and Bristol-Myers Squibb as well as 2.2 Mn sq. ft of specialist facilities, Syngene works with biotech companies pursuing leading-edge science, such as GSK, Zoetis, and Merck KGaA. | Specialization – Syngene offers end-to-end services for mammalian and microbial systems, covering diverse modalities and therapeutic areas. This primarily includes mAbs, recombinant proteins, bispecific, biosimilars, and ADCs. About us – Syngene, a leading global CRDMO with over 30 years of experience solving complex R&D challenges, delivers integrated drug discovery, development, and manufacturing services across small and large molecules. Its diverse clientele ranges from global multinationals to small and medium-sized start-ups. Syngene helps biopharma companies accelerate large molecule therapies to market through integrated biologics CDMO services, with manufacturing facilities across the U.S. and India. With a GMP capacity of 50 KL in single-use bioreactors, featuring 500-, 2,000-, and 4,000-liter units designed to deliver economies of scale, Syngene offers innovative, flexible, and efficient solutions to its clientele.
Staburo GmbH
Staburo GmbH is a data science company, specialized in biostatistics, programming (with R and SAS), data management and bioinformatics for healthcare projects. Our core competencies include Clinical Statistics, Translational Medicine & Biomarkers, Phase I, Data Transparency & Disclosure Services and Bioinformatics. Our customers are CROs (with small or no biometry department inhouse), biotech companies, international pharmaceutical companies (7 of the top 20) and medical device manufacturers.
SmartLabs
SmartLabs is challenging the status quo by delivering flexible turnkey lab programs to support workflows at every stage of development. Our transformative solutions include enterprise-grade lab environments, expert guidance, and the daily operational support you need every step of the way. | SmartLabs accelerates scientific breakthroughs by delivering cutting-edge, flexible laboratory infrastructure and comprehensive operational support. Addressing the global demand for state-of-the-art research facilities, SmartLabs provides a range of solutions, including move-in-ready suites, customized spaces, and an innovative franchise model that empowers life science innovators and investors worldwide to establish and operate advanced research environments. SmartLabs is expanding access to state-of-the-art lab facilities. This expansion enables regions worldwide to foster their own thriving research ecosystems. Building upon its established expertise, SmartLabs offers a solution that enables global real estate developers and investors to establish state-of-the-art research facilities in underserved markets. This model provides: Turnkey Lab Solutions: Comprehensive design, construction, and operational frameworks for rapidly deploying advanced lab spaces. Customizable Facilities: Lab spaces tailored to meet the specific needs of diverse research and innovation ecosystems Expert Operational Support: Leveraging SmartLabs’ proven track record in managing complex lab environments, franchisees and end-users benefit from comprehensive support in compliance, equipment maintenance, safety, and daily operations. Scalability and Flexibility: Solutions designed to accommodate a wide range of users, from startups to established enterprises, with the ability to adapt to future growth. By combining its existing flexible lab solutions with this innovative franchise approach, SmartLabs is uniquely positioned to address the global demand for advanced research facilities, empowering innovation and driving economic growth in emerging and established markets alike.
simAbs
simAbs is an EU based manufacturer of monoclonal antibodies. With our proprietary platform we are revolutionizing biomanufacturing with continuous flow technology. SimAbs provides the full range of services and support for biologics development and GMP manufacturing, specializing in sustainable biomanufacturing technologies. We are EU-GMP accredited. We are successfully delivering pre-clinical and clinical phase products. Our way to collaborate is flexible and always tailored to meet your business goals. Recently we have expanded our business into US and India and are looking for additional partnerships for global expansion.
Setsuro Tech Inc.
Setsuro Tech Inc. is a biotech startup that originated from Tokushima University and was founded in 2017. The company’s mission is to “create industries that solve your and the planet’s problems by harnessing from the potential of living organisms”. Our company provides innovative genome editing technology and contributes to the advancement of industry and human health and well-being. We use proprietary technologies to provide contract genome editing R&D services to researchers in academia and industry. Our goal is to provide genome-edited organisms broadly available to society and to advance the genome editing industry. The name of our service, PAGEs, stands for Platform App(lication) using Genome Editing by Setsuro Tech. We named it with the idea that “genome editing will add new pages to all industries worldwide and bring about a revolution in the genome editing industry”. With PAGEs, Setsuro Tech’s genome editing technology can be used to develop new traits in a wide range of species and produce useful and valuable substances. Regardless of the size of the company or the scope of the business or industry, Setsuro Tech’s PAGEs are creating breakthroughs in current production systems and providing solutions to social and environmental problems.
ScienceTrack
ScienceTrack is a Czech startup on a mission to modernize laboratory animal research with intuitive, data-driven software. From colony management to resource scheduling, our solutions streamline daily workflows, improve compliance, and support better science. Our flagship products include ZETA, a powerful animal colony management platform, and ReservAnt, a flexible tool for booking equipment, spaces, and personnel in research facilities. With user-centered design and seamless integration, ScienceTrack empowers labs to focus more on discovery and less on administration. Visit our booth to experience a live demo and learn how ScienceTrack is shaping the future of animal facility operations.
Sante Science
Sante Science is a biotech/foodtech that has developed an innovative biotechnology through upcycling to produce natural ingredients that enhance treatment and reduce the oncological chemotherapy side effects in pets and humans, improving quality of life, longevity, gut and immune health.
SAGITTA BIOTECH
Sagitta biotech is a preclinical-stage Biotech Company developing vaccines against infectious diseases and cancer. Our proprietary viral vaccine platform is based on a highly modified Measles vaccines and gave us the ability to quickly develop vaccines with a very good B and T cell response, which are safe, and are produced using a process which is identical for all pathogens (“true” vaccine platform). Sagitta is developing its own products, which will enter clinical at the end of 2025, and we are open to collaborations and co-developments on new indications. | Sagitta biotech is developping vaccines against infectious diseases and cancer from an innovative platform combining viral vectors and mRNA. The benefits of the platform are : -Very good immunogenicity (humoral and cellular) and long term protection -High safety -The manufacuring process is constant (identical for all vaccines), allowing significant shortcuts during development -The platform productivity is very high (one million dose per week from a 1 liter bioreactor, for our influenza vaccine candidate). The company is developing its own pipeline of assets, but is open to collaboration and co-development.
Royalmount Laboratories
Royalmount Labs now employs over 45 scientific, technical and support staff, and occupies 8000 sq ft of purpose built laboratory and office space. We have the latest state-of-the-art instrumentation including 13 LC-MS/MSs, 2 multimode spectrophotometer plate readers, a Luminex and 2 robotic liquid handling systems. As a partner of choice for many pharma, biotech and virtual companies, we have a very high rate of repeat business, and this is a testament to our three core principles that we consistently deliver on to our clientele – Scientific Excellence; Customer Service; On-time Delivery. With our unparalleled expertise and customized solutions, we can help you elevate your drug development process to the next level. Whether you need bioanalysis or pharmacokinetic analysis, we have the right team and the right tools. Don’t settle for less, choose Royalmount Laboratories as your partner for your drug development programs.
Ronawk, Inc.
Ronawk’s Bio-Blocks™ platform is a proprietary 3D bioprinted hydrogel system designed to replicate physiologic microenvironments with exceptional fidelity. It supports the growth and organization of over 80 cell types including primary cells, explants, and co-cultures, enabling tissue-mimetic architecture. Ronawk is advancing a pipeline that includes wound healing, regenerative medicine applications, and immune and stem cell expansion.